Angion, still reeling from past defeats, scraps a PhII kidney disease study after 'unexpected' safety event
Faced with a litany of setbacks over its lead program last year, Angion Biomedica is now reporting a new obstacle in a follow-up candidate.
Angion is discontinuing a Phase II trial evaluating oral TKI inhibitor ANG-3070, the company said Wednesday afternoon, after an unexpected safety issue popped up in the study’s treatment arm. Researchers had been enrolling patients with serious kidney diseases, including focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.